Chronic Dry Eye Patient Profiles
Patient Profile 1
- 50-year-old female
- Complains of Chronic Dry Eye and the need to use artificial tears several times a day
Relevant Medical History
- Stopped wearing contact lenses due to Chronic Dry Eye
Environmental Situation
- Has difficulty using computer for extended periods at work
- Sometimes avoids driving at night
Current Mode of Treatment
- Artificial tears
Diagnosis
- Reduced tear production likely due to ocular inflammation associated with Chronic Dry Eye
- Candidate for RESTASIS® Ophthalmic Emulsion
Patient Profile 2
- 43-year-old female
- At a general eye checkup, mentioned that use of VISINE Tears® for eye dryness has increased lately
Relevant Medical History
- Near-sighted, wears glasses
- Dry eye “no big deal;” never thought to bring up topic in prior appointments
- Two or 3 years ago started self-medicating with VISINE Tears®
Environmental Situation
- Works for a photographer
- “Sometimes I have to wear sunglasses at the studio”
Current Mode of Treatment
- Redness-removing eye drops such as VISINE Tears®
Diagnosis
- Reduced tear production likely due to ocular inflammation associated with Chronic Dry Eye
- Candidate for RESTASIS® Ophthalmic Emulsion
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.